

Disclosure: See original article for full disclosure list.

Copyright © 2010 by AAN Enterprises, Inc.


1. Ciampi de Andrade D, Rodrigues CL, Abraham R, et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. *Neurology* 2010;74:1288–1295.
2. Bianchin MM, Velasco TR, Takayanagui OM, Sakamoto AC. Neurocysticercosis, mesial temporal lobe epilepsy, and hippocampal sclerosis: an association largely ignored. *Lancet Neurol* 2006;5:20–21.
3. Hoek RM, van Kesteren RE, Smit AB, de Jong-Brink M, Geraerts WP. Altered gene expression in the host brain caused by a trematode parasite: neuropeptide genes are preferentially affected during parasitosis. *Proc Natl Acad Sci USA* 1997;94:14072–14076.
4. Vyas A, Kim SK, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioral changes induced by *Toxoplasma* infection of rodents are highly specific to aversion of cat odors. *Proc Natl Acad Sci USA* 2007;104:6442–447.
5. Morales-Montor J, Arrieta I, Del Castillo LI, Rodríguez-Dorantes M, Cerbón MA, Larralde C. Remote sensing of intraperitoneal parasitism by the host's brain: regional changes of *c-fos* gene expression in the brain of feminized cysticercotic male mice. *Parasitology* 2004;128:343–351.

## CORRECTION

### A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

In the article "A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis" by J.M. Burton et al. (*Neurology*® 2010;74:1852–1859), in figure 2, panels A, C, and D, the vitamin D3 dose was incorrectly labeled. The corrected figure is reprinted below. The editorial staff regrets the error.

Figure 2 Serum calcium and 25(OH)D results within and between patients



(A) Mean serum calcium (mmol/L) over dosing regimen in treatment group. (B) Mean serum calcium (mmol/L) of control and treatment groups at week 1 (0 IU/day vitamin D3 for treatment group), week (10,000 IU/day of vitamin D3 for treatment group), week (40,000 IU/day of vitamin D3 for treatment group), and week (discontinuation of vitamin D3 for treatment group). (C) Urinary calcium:creatinine ratios over dosing regimen in treatment group. (D) Serum 25(OH)D (nmol/L) over dosing regimen in treatment group [the value on the y-axis reflects the mean 25(OH)D level after completing the course associated with the dose of vitamin D on the x-axis].

# Neurology®

**A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis**

*Neurology* 2010;75;1029

DOI 10.1212/WNL.0b013e3181f62786

**This information is current as of September 13, 2010**

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/75/11/1029.full>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

**Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

